FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2617461034> ?p ?o ?g. }

• W2617461034 endingPage "302" @default.
• W2617461034 startingPage "292" @default.
• W2617461034 abstract "Summary Background High concentration mesalazine formulations are more convenient than conventional low concentration formulations for the treatment of ulcerative colitis ( UC ). Aim To compare the efficacy and safety of 1600 mg and 400 mg tablet mesalazine formulations. Methods Patients with mild‐to‐moderate active UC (Mayo Clinic Score >5; N=817) were randomised to 3.2 g of oral mesalazine, administered as two 1600 mg tablets once, or four 400 mg tablets twice daily. We hypothesised that treatment with the 1600 mg tablet was non‐inferior (within a 10% margin) to the 400 mg tablet for induction of clinical and endoscopic remission at week 8. Open‐label treatment with the 1600 mg tablet continued for 26‐30 weeks based on induction response. Predictors of treatment response were also explored. Results At week 8, remission occurred in 22.4% and 24.6% of patients receiving the 1600 mg and 400 mg tablets, respectively (absolute difference −2.2%, 95% CI : −8.1% to 3.8%, non‐inferiority P =.005). Endoscopic and histopathologic disease activity, leucocyte concentration and age were significantly associated with clinical remission ( P =.022, .042, .014 and .023, respectively). At week 38, 43.9% (296/675) of patients who continued treatment with the 1600 mg formulation were in remission, including 70.3% (142/202) of patients who received a reduced dose of mesalazine (1.6 g/d). The overall incidence of serious adverse events was low. Conclusions Induction therapy with 3.2 mg mesalazine using two 1600 mg tablets once‐daily was statistically and clinically non‐inferior to a twice‐daily regimen using four 400 mg tablets ( NCT 01903252)." @default.
• W2617461034 created "2017-06-05" @default.
• W2617461034 creator A5004237738 @default.
• W2617461034 creator A5008693009 @default.
• W2617461034 creator A5025934452 @default.
• W2617461034 creator A5026375446 @default.
• W2617461034 creator A5032150391 @default.
• W2617461034 creator A5032161044 @default.
• W2617461034 creator A5039561105 @default.
• W2617461034 creator A5040612375 @default.
• W2617461034 creator A5042767369 @default.
• W2617461034 creator A5045858994 @default.
• W2617461034 creator A5048464948 @default.
• W2617461034 creator A5048513411 @default.
• W2617461034 creator A5050763875 @default.
• W2617461034 creator A5052113690 @default.
• W2617461034 creator A5055840412 @default.
• W2617461034 creator A5057899912 @default.
• W2617461034 creator A5066559117 @default.
• W2617461034 creator A5068041564 @default.
• W2617461034 creator A5069444754 @default.
• W2617461034 creator A5091809254 @default.
• W2617461034 date "2017-06-01" @default.
• W2617461034 modified "2023-10-17" @default.
• W2617461034 title "Randomised non-inferiority trial: 1600 mg versus 400 mg tablets of mesalazine for the treatment of mild-to-moderate ulcerative colitis" @default.
• W2617461034 cites W1506122018 @default.
• W2617461034 cites W1907039258 @default.
• W2617461034 cites W1969818489 @default.
• W2617461034 cites W1976810311 @default.
• W2617461034 cites W1992418136 @default.
• W2617461034 cites W2011135579 @default.
• W2617461034 cites W2020019737 @default.
• W2617461034 cites W2023749526 @default.
• W2617461034 cites W2031687681 @default.
• W2617461034 cites W2037945988 @default.
• W2617461034 cites W2046382874 @default.
• W2617461034 cites W2048659220 @default.
• W2617461034 cites W2081888431 @default.
• W2617461034 cites W2085771167 @default.
• W2617461034 cites W2091606397 @default.
• W2617461034 cites W2094436918 @default.
• W2617461034 cites W2096913021 @default.
• W2617461034 cites W2103163020 @default.
• W2617461034 cites W2103205346 @default.
• W2617461034 cites W2103247145 @default.
• W2617461034 cites W2107743584 @default.
• W2617461034 cites W2110890905 @default.
• W2617461034 cites W2116318925 @default.
• W2617461034 cites W2116946774 @default.
• W2617461034 cites W2118587263 @default.
• W2617461034 cites W2120522488 @default.
• W2617461034 cites W2136867173 @default.
• W2617461034 cites W2142087713 @default.
• W2617461034 cites W2158968342 @default.
• W2617461034 cites W2165294540 @default.
• W2617461034 cites W2167161158 @default.
• W2617461034 cites W2229293842 @default.
• W2617461034 cites W2306466871 @default.
• W2617461034 cites W2321205867 @default.
• W2617461034 cites W2473786944 @default.
• W2617461034 cites W4292806894 @default.
• W2617461034 cites W4295333203 @default.
• W2617461034 doi "https://doi.org/10.1111/apt.14164" @default.
• W2617461034 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28568974" @default.
• W2617461034 hasPublicationYear "2017" @default.
• W2617461034 type Work @default.
• W2617461034 sameAs 2617461034 @default.
• W2617461034 citedByCount "25" @default.
• W2617461034 countsByYear W26174610342017 @default.
• W2617461034 countsByYear W26174610342018 @default.
• W2617461034 countsByYear W26174610342019 @default.
• W2617461034 countsByYear W26174610342020 @default.
• W2617461034 countsByYear W26174610342021 @default.
• W2617461034 countsByYear W26174610342022 @default.
• W2617461034 countsByYear W26174610342023 @default.
• W2617461034 crossrefType "journal-article" @default.
• W2617461034 hasAuthorship W2617461034A5004237738 @default.
• W2617461034 hasAuthorship W2617461034A5008693009 @default.
• W2617461034 hasAuthorship W2617461034A5025934452 @default.
• W2617461034 hasAuthorship W2617461034A5026375446 @default.
• W2617461034 hasAuthorship W2617461034A5032150391 @default.
• W2617461034 hasAuthorship W2617461034A5032161044 @default.
• W2617461034 hasAuthorship W2617461034A5039561105 @default.
• W2617461034 hasAuthorship W2617461034A5040612375 @default.
• W2617461034 hasAuthorship W2617461034A5042767369 @default.
• W2617461034 hasAuthorship W2617461034A5045858994 @default.
• W2617461034 hasAuthorship W2617461034A5048464948 @default.
• W2617461034 hasAuthorship W2617461034A5048513411 @default.
• W2617461034 hasAuthorship W2617461034A5050763875 @default.
• W2617461034 hasAuthorship W2617461034A5052113690 @default.
• W2617461034 hasAuthorship W2617461034A5055840412 @default.
• W2617461034 hasAuthorship W2617461034A5057899912 @default.
• W2617461034 hasAuthorship W2617461034A5066559117 @default.
• W2617461034 hasAuthorship W2617461034A5068041564 @default.
• W2617461034 hasAuthorship W2617461034A5069444754 @default.
• W2617461034 hasAuthorship W2617461034A5091809254 @default.
• W2617461034 hasBestOaLocation W26174610341 @default.
• W2617461034 hasConcept C120665830 @default.

• next